Twist Bioscience Expects Q2 FY24 Sales Of $70M-$71M Versus Consensus Of $70.01M, With Gross Margin Of 39%
Portfolio Pulse from Benzinga Newsdesk
Twist Bioscience anticipates Q2 FY24 sales to be between $70M-$71M, closely aligning with the consensus estimate of $70.01M. The company also projects a gross margin of 39% for the same period.
February 02, 2024 | 12:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Twist Bioscience expects Q2 FY24 sales to range between $70M-$71M, aligning with consensus estimates of $70.01M, and anticipates a gross margin of 39%.
The company's sales forecast closely matches consensus estimates, indicating management's confidence in their business performance. The expected gross margin of 39% suggests operational efficiency and profitability, which could positively influence investor sentiment and potentially lead to a short-term uptick in TWST's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100